Psychedelic Stocks,Shroom News ATAI Life Sciences Preparing for a $100 Million IPO By Dennis Mutua April 22, 2021 Clinical stage Bioscience Company focusing on treatment of mental illness ATAI Life Sciences says that it’s anticipating to raise $100 million from its upcoming initial public offering. The company made its IPO regulatory filing...
Psychedelic Stocks,Shroom News Prof Benjamin Kelmendi Appointed to the Scientific Advisory Board of Lobe Sciences By Dennis Mutua April 21, 2021 Growth oriented life sciences company specializing on psychedelics Lobe Sciences Ltd (CSE: LOBE) (OTC: GTSIF) has appointed Professor Benjamin Kelmendi to its scientific advisory board. Professor Kelmendi serves as an assistant Pr...
Featured,Shroom News,Spotlight Stock Halucenex Signs Agreement With Sixth Wave to Progress Research of Hallucinogenic Mushrooms By Dennis Mutua April 20, 2021 Life sciences development company focusing on novel psychedelics compounds to treat mental illnesses Halucenex Life Sciences has signed a non-binding letter of agreement (LOI) of agreement with Sixth Wave, a leading nanotechnology...
Psychedelic Stocks,Shroom News Silo Wellness Signs a Patent Agreement of Psilocybin Nasal Spray with Jungle Med By Dennis Mutua April 16, 2021 Psychedelics focused wellness company Silo Wellness Inc. (CSE: SILO) announced having entered an intellectual property licensing agreement of psilocybin with Jungle Med Inc. to exclusively produce, advertise, promote, and distribu...
Featured,Shroom News Psychedelics Bill Authorized by Senator Scott Weiner Passed by Senate Health Committee By Dennis Mutua April 15, 2021 United States Senate Health Committee passed a bill aimed at decimalizing use of psychedelics drugs authorized by the Senator of San Francisco Scott Weiner. The committee voted 6:1 in favor of the psychedelics bill. Senator Wei...
Psychedelic Stocks,Shroom News Research Shows Psilocybin May be Used for its Antidepressant Properties Without Any Psychedelic Experiences By Dennis Mutua April 14, 2021 A recent study conducted by the University of Maryland shows how psilocybin can be used for its antidepressant properties without the need of the user having any prior experience with psychedelics. This research was financed by...
Featured,Shroom News,Spotlight Stock Awakn Unveils New Digital Unit Focused on Improving the Effectiveness of Psychedelics Therapy By Dennis Mutua April 13, 2021 Clinical biotechnology company majoring on researching, developing, and delivering psychedelic new molecular drugs Awakn Life Sciences Inc. has unveiled a new digital wing which will be focusing on using advanced analytics to impr...
Featured,Shroom News,Spotlight Stock Mydecine Innovations Unveils Four Novel Psychedelic Drugs By Dennis Mutua April 09, 2021 Biotech and life sciences company focusing on innovative solutions for treating mental illness and enhancing vitality Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) has unveiled four novel psychedelic drug candidates. Citi...